Integra Lifesciences Holdings (IART) Short term Debt (2009 - 2026)

Integra Lifesciences Holdings' Short term Debt history runs 16 years deep, the most recent figure standing at $38.8 million for Q1 2026.

• In Q1 2026, Short term Debt changed 0.0% year-over-year to $38.8 million; the TTM figure through Mar 2026 stood at $38.8 million (changed 0.0% YoY), while the FY2025 annual figure was $38.8 million, down 93.24% from the prior year.
• Short term Debt came in at $38.8 million for Q1 2026 at Integra Lifesciences Holdings, roughly flat from $38.8 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $573.2 million in Q4 2024 to a low of $4.8 million in Q2 2023.
• A 5-year average of $71.8 million and a median of $38.8 million in 2025 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt jumped 399.98% in 2024 and slumped 93.24% in 2025, its largest moves.
• Integra Lifesciences Holdings' Short term Debt stood at $38.1 million in 2022, then sank by 74.59% to $9.7 million in 2023, then jumped by 5816.9% to $573.2 million in 2024, then plunged by 93.24% to $38.8 million in 2025, then changed by 0.0% to $38.8 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $38.8 million, $38.8 million, and $38.8 million for Q1 2026, Q4 2025, and Q2 2025 respectively.

Peer Comparison